Clinical Research in Radiation Oncology of Lung Cancer: Why We Fail(ed)?

  • Branislav Jeremić
Part of the Medical Radiology book series (MEDRAD)


Clinical research in radiation oncology of lung cancer can bring important advances in the field of optimized treatment approaches in this disease. However, such a research has been a subject of many controversies, in particular in the light of lack of adequate number and quality of clinical trials which could have changed our standard policies. To address the comprehensive issue of clinical research in radiation oncology of lung cancer, several aspects will be considered: clinical research generals, technological addictions, clinical failures, and some of existing, rather controversial issues identified. Finally, some of possible solutions for the current, grossly unfavorable, situation will be discussed.


Lung Cancer Cell Lung Cancer Small Cell Lung Cancer Radiation Oncologist Induction Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR (2005) Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study–CALGB 9534. Clin Lung Cancer 7:47–53PubMedCrossRefGoogle Scholar
  2. Belani CP, Wang W, Johnson DH (2005a) Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23:3760–3767PubMedCrossRefGoogle Scholar
  3. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr (2005b) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883–5891PubMedCrossRefGoogle Scholar
  4. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C (2007) EORT LCGC and RT Group. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972–22973). Eur J Cancer 43:114–121PubMedCrossRefGoogle Scholar
  5. Clamon G, Herndon J, Cooper R (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4–11PubMedGoogle Scholar
  6. Curran WJ Jr, Scott C, Langer C, Komaki R, Lee JS, Hauser S (2000) Phase III comparison of sequential Vs cancer (NSCLC): Initial report of Radiation Therapy Oncology Group concurrent chemoradiation for pts with unresected stage III non small cell lung (RTOG 9410). Proc Am Soc Clin Oncol 19:484a (Abstract 1891)Google Scholar
  7. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940–945PubMedCrossRefGoogle Scholar
  8. El Sharouni SY, Kal HB, Battermann JJ (2003) Accelerated regrowth of non-small cell lung tumors after induction chemotherapy. Br J Cancer 89:2184–2189PubMedCrossRefGoogle Scholar
  9. Fried DB, Morris DE, Poole C et al (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4785–4793CrossRefGoogle Scholar
  10. Gandara DR, Chansky K, Albain KS et al (2006) Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small cell lung cancer: a phase II Southwest Oncology Group study (S9504). Clin Lung Cancer 8:116–121PubMedCrossRefGoogle Scholar
  11. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L (2007) International association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706–714Google Scholar
  12. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L, Hoosier Oncology Group;US Oncology (2008) Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755–5760PubMedCrossRefGoogle Scholar
  13. Huncharek M, McGarry R (2004) A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 9:665–672PubMedCrossRefGoogle Scholar
  14. Jeremic B (2006) Timing of concurrent radiotherapy and chemotherapy in limited-disease small-cell lung cancer: meta-analysis of meta-analyses. Int J Radiat Oncol Biol Phys 64:981–982PubMedCrossRefGoogle Scholar
  15. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S (1997) Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer. J Clin Oncol 15:893–900PubMedGoogle Scholar
  16. Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G (1999) The role of radiation therapy in the combined modality treatment of patients with extensive disease small-cell lung cancer (ED SCLC): a randomized study. J Clin Oncol 17:2092–2099PubMedGoogle Scholar
  17. Langer CJ, Moughan J, Movsas B, Komaki R, Ettinger D, Owen J, Wilson JF (2005) Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature. Lung Cancer 48:93–102PubMedCrossRefGoogle Scholar
  18. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V (2001) Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California cancer consortium phase II trial. J Clin Oncol 19:42–447Google Scholar
  19. Le Chevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix W (1992) Significant effect of adjuvant chemotherapy on survival in locally advanced non small cell lung carcinoma. J Natl Cancer Inst 84:58 (letter)Google Scholar
  20. Movsas B, Moughan J, Komaki R et al (2003) Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol 21:4553–4559PubMedCrossRefGoogle Scholar
  21. Pijls-Johannesma MCG, de Ruysscher D, Lambin P et al (2004) Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev No. 4Google Scholar
  22. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M (1999) Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 52:137–148PubMedCrossRefGoogle Scholar
  23. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R (1995) Radiation Therapy Oncology Group 88–08 and Eastern Cooperative Oncology Group 4588: Preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J Natl Cancer Inst 87:198–205PubMedCrossRefGoogle Scholar
  24. Schaake-Koning C, van der Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524–530PubMedCrossRefGoogle Scholar
  25. Sekine I, Nokihara H, Sumi M, Saijo N, Nishiwaki Y, Ishikura S, Mori K, Tsukiyama I, Tamura T (2006) Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 1:810–815PubMedCrossRefGoogle Scholar
  26. Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE (2008) Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457–2463PubMedCrossRefGoogle Scholar
  27. Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 28(340):265–271CrossRefGoogle Scholar
  28. Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20:4191–4198PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Institute of Lung DiseasesSremska KamenicaSerbia

Personalised recommendations